BRTX.US BioRestorative Therapies Inc

Healthcare Biotechnology USA Stocks
1.49 USD
Close of Nov 13, 2026
0.1417 2.93
Market cap
USD 2.06M
P/E
-
P/B
0.68x
ROE
-284.8%
Dividend yield
13.15%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.

Is BRTX.US undervalued?

Graham number

The Graham number of BioRestorative Therapies Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BioRestorative Therapies Inc fundamental analysis

No fundamental analysis for BioRestorative Therapies Inc yet.

BioRestorative Therapies Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BioRestorative Therapies Inc

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of p…

Full company profile